| Name | Title | Contact Details |
|---|
Hospital Billing and Collection Services is a New Castle, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VSP GlobalSM offers world-class products and services to eyecare professionals, employers, and more than 55 million members through a group of leading companies providing comprehensive eyecare coverage, access to cutting-edge frame styles and brands, design of custom interiors and merchandising systems, innovative e-commerce and practice management solutions, and technologically advanced lab services.
Starkey Hearing Technologies is much more than the hearing aids we produce. We are in the business of connecting people and changing lives. We believe being able to hear the world and the people around us is as essential to the human experience as breathing. As a world leader in manufacturing and delivering advanced hearing solutions, our goal is to bring people together and make lives richer by empowering individuals to reach their full potential in life. In 1967, William F. Austin founded our company with the simple premise, "Alone we can`t do much. Together, we can change the world." We live that vision every day – and it`s why with every Starkey Hearing Technologies` product purchased, we donate to the Starkey Hearing Foundation to help more people in need around the world receive the gift of hearing. To date we have given over 1 million hearing aids to people around the world.
CCStpa is a Eagan, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.